Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. Issue 12 (1st December 2016)

• Record Type: Journal Article
• Authors: Pilorge, Sylvain; Harel, Stephanie; Ribrag, Vincent; Larousserie, Frédérique; Willems, Lise; Franchi, Patricia; Legoff, Marielle; Biau, David; Anract, Philippe; Roux, Christian; Blanc-Autran, Estelle; Delarue, Richard; Gisselbrecht, Christian; Ketterer, Nicolas; Recher, Christian; Bonnet, Christophe; Peyrade, Frederic; Haioun, Corinne; Tilly, Hervé; Salles, Gilles; Brice, Pauline; Bouscary, Didier; Deau, Bénédicte; Tamburini, Jerome
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 12(2016:Dec.)
• Page Start: 2820
• Page End: 2826
• Publication Date: 2016-12-01
• Subjects: aa-IPI -- DLBCL -- radiotherapy -- rituximab -- primary bone lymphoma; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2016.1177180
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare DLBCL location variant. We treated 76 PB-DLBCL patients by immuno-chemotherapy, resulting in an 84% sustained complete remission rate and a 78.9% survival over a 4.7-year median follow-up period. Ann Arbor stage IV and high age-adjusted international prognostic index were predictive of adverse outcome in univariate analysis. In multivariate analysis using a Cox model, only aa-IPI predicted long-term survival. While based on a limited number of cases, we suggested that radiotherapy may be useful as a consolidation modality in PB-DLBCL. We also suggested that positron emission tomography/CT scan should be interpreted with caution due to a persistent [18F]fluorodeoxyglucose [18FDG] uptake of bone lesions even after remission in some in PB-DLBCL patients. Our study based on a homogeneous cohort of PB-DLBCL patients confirmed the favorable outcome of this DLBCL variant and support the implementation of prospective clinical trials in this disease.